欧州の大腸がん検診および診断市場：分析と予測（2023年～2033年）

欧州の大腸がん検診および診断の市場規模は、2023年に41億9,000万米ドルとなりました。

同市場は、2033年には73億米ドルに達すると予測され、予測期間の2023年～2033年のCAGRは5.72%になるとみられています。大腸がん検診および診断分野は、大腸がん発生の急増、ヘルスケアシステムへの財政負担の増大、ゲノム・分子診断の進歩、大腸がん検診ニーズの高まりなど、さまざまな要因の影響を受けています。

欧州の大腸がん検診および診断市場は、いくつかの要因によって大きな成長を遂げています。大腸がん罹患率の上昇と高齢化が相まって、効果的なスクリーニングと診断ツールに対する需要が高まっています。さらに、早期発見を促進する啓発キャンペーンや政府のイニシアチブの増加が市場拡大に寄与しています。ゲノミクスと分子診断学の進歩はスクリーニング法の精度と効率を高め、市場の成長をさらに促進しています。さらに、ヘルスケアシステムに対する財政負担の増大は、費用対効果が高く効率的なスクリーニングソリューションの重要性を強調しています。大腸がん検査に対する需要の急増に伴い、欧州市場では、進化する医療ニーズに対応し、患者の転帰を改善するための技術革新が顕著に進展しています。

当レポートでは、欧州の大腸がん検診および診断市場について調査し、市場の概要とともに、タイプ別、エンドユーザー別、国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

第1章 市場

• 市場の見通し
• 業界の展望

第2章 大腸がん検診および診断市場（地域別）

• 欧州
  • 主な調査結果
  • 市場力学
  • 市場規模と予測
• 競合ベンチマーキング
  • 主要な戦略と展開
• 企業プロファイル
  • Epigenomics AG
  • Mainz Biomed NV
  • Novigenix SA

List of Figures

• Figure 1: Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 2: Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
• Figure 3: Europe Colorectal Cancer Screening and Diagnostic Market (by Type), $Billion 2022 and 2033
• Figure 4: Europe Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion 2022 and 2033
• Figure 5: Colorectal Cancer Screening and Diagnostic Market: Research Methodology
• Figure 6: Primary Research Methodology
• Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 8: Top-Down Approach (Segment-Wise Analysis)
• Figure 9: Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Country), January 2019-April 2023
• Figure 10: Colorectal Cancer Screening and Diagnostic Market, Patent Analysis (by Year), January 2019-April 2023
• Figure 11: Stool-Based Molecular Tests, by Company
• Figure 12: Colorectal Cancer Screening and Diagnostic Market, Impact Analysis
• Figure 13: Number of Colorectal Cancer Cases Globally, 2020- 2040
• Figure 14: Cancer Survival Rate with Respect to Stage of Detection, 2022
• Figure 15: Colorectal Cancer Screening and Diagnostic Market, %Share (by Region), 2022 and 2033
• Figure 16: Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 17: Europe Colorectal Cancer Screening and Diagnostic Market (by End User), $Billion, 2022-2033
• Figure 18: Europe Colorectal Cancer Screening and Diagnostic Market (by Product), $Billion, 2022-2033
• Figure 19: Europe Colorectal Cancer Screening and Diagnostic Market (by Country), Share (%), 2022 and 2033
• Figure 20: Germany Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 21: U.K. Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 22: France Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 23: Spain Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 24: Italy Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 25: Rest-of-Europe Colorectal Cancer Screening and Diagnostic Market, $Billion, 2022-2033
• Figure 26: Colorectal Cancer Screening and Diagnostic Market, Number of Key Developments and Strategies, January 2020-April 2023
• Figure 27: Funding Activities, January 2020-April 2023
• Figure 28: New Offerings, January 2020-April 2023
• Figure 29: Business Expansion, January 2020-April 2023
• Figure 30: Mergers and Acquisitions, January 2020-April 2023
• Figure 31: Partnerships and Collaborations, January 2020-April 2023
• Figure 32: Epigenomics AG: Product Portfolio
• Figure 33: Epigenomics AG: Overall Financials, $Million, 2020-2022
• Figure 34: Epigenomics AG: Net Revenue (by Segment), $Million, 2020-2022
• Figure 35: Epigenomics AG: Net Revenue (by Region), $Million, 2020-2022
• Figure 36: Mainz Biomed NV: Product Portfolio
• Figure 37: Mainz Biomed NV: Overall Financials, $Million, 2020-2022
• Figure 38: Novigenix SA: Product Portfolio

List of Tables

• Table 1: Colorectal Cancer Screening and Diagnostic Market, Key Developments Analysis, January 2018-April 2023
• Table 2: Key Questions Answered in the Report
• Table 3: Colorectal Cancer Screening and Diagnostic Market, Product Pipeline
• Table 4: Examples of Colorectal Cancer Screening Initiatives
• Table 5: Examples of Product Launches and Approval in Asia-Pacific
• Table 6: Europe Colorectal Cancer Screening and Diagnostic Market, Impact Analysis

The Europe Colorectal Cancer Screening and Diagnostic Market Expected to Reach $7.30 Billion by 2033

Introduction to Europe Colorectal Cancer Screening and Diagnostic Market

The Europe colorectal cancer screening and diagnostic market was valued at $4.19 billion in 2023 and is expected to reach $7.30 billion by 2033, growing at a CAGR of 5.72% during the forecast period 2023-2033. The colorectal cancer screening and diagnostic sector are influenced by various factors such as the escalating occurrence of colorectal cancer, heightened financial strain on healthcare systems, advancements in genomics and molecular diagnostics, and a rising need for colorectal cancer examination.

Market Introduction

The Europe colorectal cancer screening and diagnostic market are experiencing significant growth propelled by several factors. Rising incidences of colorectal cancer, coupled with an aging population, are driving the demand for effective screening and diagnostic tools. Additionally, increased awareness campaigns and government initiatives promoting early detection contribute to market expansion. Advances in genomics and molecular diagnostics have enhanced the accuracy and efficiency of screening methods, further fueling market growth. Moreover, the growing financial burden on healthcare systems emphasizes the importance of cost-effective and efficient screening solutions. With a surge in demand for colorectal cancer testing, the European market is witnessing notable developments in technology and innovation to meet evolving healthcare needs and improve patient outcomes.

Market Segmentation:

Segmentation 1: by Type

• Screening
• Diagnostic

Segmentation 2: by End User

• Hospitals and Clinics
• Clinical Laboratories
• Other End Users

Segmentation 3: by Country

• Germany
• France
• Italy
• U.K.
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Product/Innovation Strategy: The product segment helps the reader understand the different types of colorectal cancer screening and diagnostic methodologies. Moreover, the study provides the reader with a detailed understanding of the colorectal cancer screening and diagnostic market by end-user application (hospitals and clinics, clinical laboratories, and other end users), type (blood-based tests, stool-based tests, colonoscope, biomarker test, and other test types), and region (Europe)

Growth/Marketing Strategy: The colorectal cancer screening and diagnostic market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and new product launches. The favored strategy for the companies has been partnerships and collaborations to strengthen their position in the colorectal cancer screening and diagnostic market.

Competitive Strategy: Key players in the colorectal cancer screening and diagnostic market analyzed and profiled in the study involve major colorectal cancer screening kit manufacturers (stool DNA test, FIT/FOB tests), biomarker testing kit manufacturers, sigmoidoscope, and colonoscope manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the colorectal cancer screening and diagnostic market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations are expected to aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Some of the prominent names established in this market are:

• Epigenomics AG
• Mainz Biomed NV
• Novigenix SA

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1 Markets

• 1.1 Market Outlook
  • 1.1.1 Market Overview
  • 1.1.2 Product Definition
  • 1.1.3 Inclusion and Exclusion Criteria
  • 1.1.4 Key Findings
• 1.2 Industry Outlook
  • 1.2.1 Regulatory Framework
    • 1.2.1.1 Regulatory Framework in Europe
  • 1.2.2 Reimbursement Scenario
    • 1.2.2.1 Fecal Immunochemical Testing/Fecal Occult Blood Testing
    • 1.2.2.2 Molecular Testing
  • 1.2.3 Patent Analysis
    • 1.2.3.1 Patent Filing Trend (by Country)
    • 1.2.3.2 Patent Filing Trend (by Year)
  • 1.2.4 Key Trends
    • 1.2.4.1 Rise of At-Home Colorectal Cancer Screening
    • 1.2.4.2 Multimodal Approaches to Colorectal Cancer Screening
    • 1.2.4.3 Use of Gut Microbiota in Colorectal Cancer Diagnosis
  • 1.2.5 COVID-19 Impact
    • 1.2.5.1 Impact of COVID-19 on Colorectal Cancer Screening and Diagnostic Market
    • 1.2.5.2 Pre-COVID-19 Phase
    • 1.2.5.3 During-COVID-19 Phase
    • 1.2.5.4 Post-COVID-19 Phase
  • 1.2.6 Product Landscape
  • 1.2.7 Product Pipeline
  • 1.2.8 Business Dynamics
    • 1.2.8.1 Impact Analysis
    • 1.2.8.2 Business Drivers
      • 1.2.8.2.1 Rising Incidence of Colorectal Cancer and Increasing Financial Burden on Healthcare
      • 1.2.8.2.2 Advances in Genomics and Molecular Diagnostics
      • 1.2.8.2.3 Growing Demand for Colorectal Cancer Testing
      • 1.2.8.2.4 Earlier Cancer Detection Enabling Reduced Treatment Cost
    • 1.2.8.3 Business Restraints
      • 1.2.8.3.1 Limited Sensitivity of FIT/FOBt Testing Kits
      • 1.2.8.3.2 Challenges with Sample Collection
    • 1.2.8.4 Business Opportunities
      • 1.2.8.4.1 Expansion of Screening Programs
      • 1.2.8.4.2 Emerging Markets Proposing Significant Untapped Potential

2 Colorectal Cancer Screening and Diagnostic Market (by Region)

• 2.1 Europe
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
    • 2.1.2.1 Impact Analysis
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 Europe Colorectal Cancer Screening and Diagnostic Market (by End User)
    • 2.1.3.2 Europe Colorectal Cancer Screening and Diagnostic Market (by Product)
    • 2.1.3.3 Europe Colorectal Cancer Screening and Diagnostic Market (by Country)
      • 2.1.3.3.1 Germany
      • 2.1.3.3.2 U.K.
      • 2.1.3.3.3 France
      • 2.1.3.3.4 Spain
      • 2.1.3.3.5 Italy
      • 2.1.3.3.6 Rest-of-Europe
• 2.2 Competitive Benchmarking
  • 2.2.1 Key Strategies and Developments
    • 2.2.1.1 Funding Activities
    • 2.2.1.2 New Offerings
    • 2.2.1.3 Business Expansion
    • 2.2.1.4 Mergers and Acquisitions
    • 2.2.1.5 Partnerships and Collaborations
• 2.3 Company Profile
  • 2.3.1 Epigenomics AG
    • 2.3.1.1 Company Overview
    • 2.3.1.2 Role of Epigenomics AG in the Colorectal Cancer Screening and Diagnostic Market
    • 2.3.1.3 Financials
    • 2.3.1.4 Recent Developments
    • 2.3.1.5 Analyst Perspective
  • 2.3.2 Mainz Biomed NV
    • 2.3.2.1 Company Overview
    • 2.3.2.2 Role of Mainz Biomed NV in the Colorectal Cancer Screening and Diagnostic Market
    • 2.3.2.3 Financials
    • 2.3.2.4 Recent Developments
    • 2.3.2.5 Analyst Perspective
  • 2.3.3 Novigenix SA
    • 2.3.3.1 Company Overview
    • 2.3.3.2 Role of Novigenix SA in the Colorectal Cancer Screening and Diagnostic Market
    • 2.3.3.3 Recent Developments
    • 2.3.3.4 Analyst Perspective